INTRODUCTION
The incidence, outcome, and severity of many infectious and autoimmune diseases differ between women and men [1] . A strong sex bias is observed for many autoimmune diseases [2] , which are much more common in women, including autoimmune thyroid diseases, systemic sclerosis and systemic lupus erythematosus. Furthermore, the incidence and severity of several microbial infections, including malaria and tuberculosis [3] , influenza [4] , hepatitis [5] , and HIV-1 [6] are different between the sexes [7] . In HIV-1 infection, clinical studies have shown faster disease progression and stronger immune activation in women compared with men for the same level of viral replication, as well as better control of initial viremia in women during primary infection. This review will summarize recent findings on the immune mechanisms that underlie sex-specific differences in the manifestations of HIV-1 disease, and in particular, the role of immune activation.
DIRECT AND INDIRECT EFFECTS OF SEX CHROMOSOMES ON ANTIVIRAL IMMUNITY
In general, women have been reported to display an overall reduced susceptibility to viral infections, potentially because of stronger innate, cellular, and humoral immune responses compared with men [1, [8] [9] [10] [11] . This enhanced level of immune responses and activation, however, can have detrimental consequences for disease outcomes resulting from immune pathology, in particular for chronic persistent infections. The biological mechanisms that lead to these sex-specific differences in the manifestations of viral infections are incompletely understood, but could result from sex-specific environmental risk factors, sex differences in the microbiome [12] , steroid hormones secreted by gonads [9, 13] , and direct effects of X and Y chromosome-linked factors [14] [15] [16] (Fig. 1) .
Several genes on the X chromosome can potentially influence immunocompetence [15] , in particular those loci on the X-chromosome encoding for genes involved in immune regulation. These include for example foxp3, the lineage-defining transcription factor of regulatory T cells, IL-2Rg, a common cytokine receptor, and the pattern recognition receptors (PRR) Tlr7 and Tlr8, which are known to sense HIV-1 single-stranded RNA (ssRNA). Importantly, X-chromosome inactivation is considered to be a random process and an estimated 10% of the X chromosome escapes inactivation [17] , which may lead to an overexpression of certain gene products. For example, Tlr7 mRNA was shown to be higher expressed in cells from women compared with men [18] .
Apart from the direct role of X-linked factors, the indirect effects of sex chromosomes, namely the immune modulation by steroid hormones, play a prominent role in sex-specific outcomes. Estrogens mediate their immunomodulatory function through binding to the intracellular estrogen receptor a or b. Estrogen receptor a is ubiquitously expressed by immune cells and signals via estrogen receptor a or b complexes that translocate to the nucleus, thereby regulating transcriptional activity of many genes involved at different stages of immune-cell maturation, as well as regulation and maturation of immune responses. However, the precise molecular mechanisms and pathways leading to sex-based differences are largely unknown and require further investigation [19] . In this review, we will discuss the consequences of these sexspecific differences in immunity for HIV-1 disease.
SEX DIFFERENCES IN HIV-1-ASSOCIATED IMMUNE ACTIVATION AND IMMUNOPATHOLOGY
Sex differences have been described for diverse aspects of HIV-1 infection and disease, including transmission, pathogenesis, morbidity, mortality, and responses to antiretroviral treatment [8, 20] . In addition to sex and sex-specific social and political factors, including sex inequalities and limited access to healthcare, the influence of biological factors also importantly contributes to the differential outcome of HIV-1 infection between women and men. Sex differences in HIV-1 immunopathogenesis will be the topic of this review article, with particular focus on the role of immune activation. Understanding the biological factors underlying these sex differences is important, as women are overproportionally affected by the HIV-1 epidemic, and in particular young women in sub-Saharan Africa. HIV-1 infection represents now a leading cause of death in women in their reproductive age [21] and according to the WHO, HIV/AIDS has become the main cause of death in adolescent women [22] .
Marked sex differences in the manifestations of HIV-1 infections have been described in several larger cohort studies [23, 24] . In primary HIV-1 infection, women tend to have lower plasma viral load levels compared with men [25] . However, in chronic infections, women with the same viral load as men have a 1.6-fold higher risk of developing AIDS or, equivalently, women with half the viral load of men have a similar time to AIDS progression as men [23] . Interestingly, sex differences in viral load are more pronounced in individuals with higher CD4 þ T cell counts, suggesting that differences in viral load might be lost at later disease stages [26] . Furthermore, sex-specific differences in CD4 þ T cell counts have been reported in several studies, with higher CD4 þ T cell counts in HIV-1infected women compared with men [27] [28] [29] [30] [31] [32] . The precise mechanisms responsible for these reported sex differences in viral load and CD4 þ T cell counts remain unknown. However, a role of sex hormones has been postulated [23] , based on the observation of fluctuating viral loads during the menstrual cycle [33] and lack of differences in CD4 þ T cell counts between women and men above the age of 50 years [34] .
KEY POINTS
Sex differences exist in the manifestations of primary and chronic HIV-1 infection.
Sex-dependent differences in the TLR7/IFNa pathway lead to higher levels of ISG expression in women, resulting in stronger immune activation in HIV-1-infected women.
These sex differences in the inflammatory response to HIV-1 might be responsible for the described faster disease progression in women compared with men after controlling for viral load levels.
Estrogens can positively regulate the TLR7/IFNa pathway through cell-intrinsic pathways.
Untreated chronic HIV-1 infection is characterized by strong systemic immune activation that persists at elevated levels compared with non-HIV-1-infected individuals, even following effective antiretroviral therapy. This immune activation is characterized by B-and T cell activation [35] , high T cell turnover [36] , and increased levels of proinflammatory mediators [37] . It is now well established that the level of immune activation is a strong predictor for HIV-1 disease progression [38] , with some studies demonstrating that the level of immune activation serves as a better correlate than plasma viral load levels [39] [40] [41] . Even HIV-1 controllers have been shown to have abnormally high T cell activation levels compared with HIV-1negative individuals [42] . Interestingly, plasma type I interferon (IFN) levels inversely correlated with CD4 þ T cell counts and positively with plasma viral load levels and activation status of CD8 þ T cells [43] . Chronic immune activation and inflammation have also been associated with accelerated immune aging and non-AIDS-related morbidities and mortalities, including cardiovascular diseases [44, 45] and non-AIDS-defining malignancies. Taken together, the level of immune activation clearly contributes to HIV-1 disease progression and can differ between women and men [9] .
Very recently, Ren et al. reported the development and characterization of a nonhuman primate model that reflected the sex differences observed in HIV-1 infection in humans [46 & ]. Rhesus macaques that were infected intrarectally with simian HIV showed sex differences in gut innate immune responses, with females mounting a faster and more robust local mucosal proinflammatory immune response in comparison with males. Moreover, analysis of the bacterial community structures in the rectal mucosa revealed a significantly higher expansion of specific bacterial subsets in the rectal mucosa of female than male macaques during acute infection. This study suggests that the local mucosal innate immune activation that is augmented early in infection and changes in the microbiome could contribute to faster disease progression in women [46 & ]. A key role for translocation of microbial products from the intestinal lumen to the systemic circulation, because of damages in intestinal barriers, has been suggested as a driver of persistent immune activation in HIV-1 infections [47] . Among those translocated, commensal microbial products are potent activators of several PRRs [48] , leading to the production of proinflammatory cytokines, including TNFa. The composition of the gut microbiome might therefore have an impact on immune activation. Recent findings suggest a bidirectional interaction between the microbiome and sex hormones [16] . In one study [49] , the microbiota of opposite-sex twin pairs was assessed. Interestingly, before puberty, the microbiome between opposite sexes was as similar as the microbiome of same-sex twin pairs. However after puberty, the microbiome became more disparate, suggesting that hormonal levels can shape the microbiome composition [49] . Taken altogether, there is emerging evidence that [25] • TLR7/8 expression levels [18] • IRF5 basal levels [62]
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sex hormones can modulate the microbiome, and thereby influence the expression of sex-related phenotypes [16] .
INNATE SENSING OF HIV-1
The innate immune system plays a central role in the sensing of microbial infections and in initiating antiviral immune responses [50] . HIV-1 encodes for multiple pathogen-associated molecular patterns that can be recognized by nucleic acid sensors of the Toll-like receptor (TLR) family, and the recently discovered intracellular PRRs IFN-inducible protein 16 (IFI16) and cyclic GMP-AMP synthase (cGAS) that sense reverse transcription products early in the viral replication cycle (Fig. 1) .
IFI16, an IFN-stimulated gene (ISG), binds DNA products of HIV-1 reverse transcription, including truncated DNA and a DNA segment of the HIV-1 long terminal repeat region [51] . Knockdown of IFI16 results in increased permissiveness toward HIV-1 infection and enhanced virus replication, suggesting that IFI16 functions as a viral sensor and restriction factor. The recently identified enzyme cyclic GMP-AMP synthase, a cytosolic DNA sensor, triggers the production of type I IFN and other cytokines after sensing of HIV-1 and other retroviruses [52, 53] . Both intracellular sensors signal via stimulator of interferon genes, thereby activating downstream TBK1 and the transcription factors IFN-regulatory factor (IRF) 3 and IRF7 to drive cell intrinsic innate immune responses [50] .
Among the TLR family, TLR3, 7, 8, and 9 that are confined to the endosomes [54] have been described to sense several nucleic acid intermediates generated during the viral life cycle [55, 56] . TLR3 is activated by double-stranded RNA, TLR7 by ssRNA and short double-stranded RNA, and TLR8 detects short ssRNA and ssRNA breakdown products [57] . Intracellularly, HIV-1 ssRNA can be recognized by TLR7 on plasmacytoid dendritic cells (pDCs) and TLR8 on monocytes and XCR1 þ dendritic cells. However, during the viral life cycle, a dimeric state of HIV-1 viral RNA is present [58] , which potentially allows for the recognition by TLR3 on monocytes and XCR1 þ dendritic cells [59] . Although there is solid evidence for TLR7-mediated activation of pDCs by HIV-1 ssRNA [55] resulting in type I IFN production [60] , other cell types appear to be less sensitive to HIV-1encoded pathogen-associated molecular patterns . Ligand engagement of TLRs also leads to the activation of proinflammatory and antimicrobial responses via pathways involving JAK/Stat signaling, NF-kB, and IRF3, IRF5, and IRF7 [61] . Recent data by our group suggest a critical role for IRF5 in mediating the observed sex differences in IFNa-production by pDCs in response to TLR7 stimulation. Basal levels of IRF5 in pDCs from women were significantly higher compared with men and correlated with the percentage of IFNasecreting pDCs [62 & ]. Interestingly, knockout of the Esr1 gene in the hematopoietic compartment or dendritic cells lineage of B6 mice reduced IRF5 mRNA expression in pDCs and IFNa production compared with wt mice, indicating that ERa can modulate IRF5 levels and thus the IFNa pathway. Taken together, sensing of HIV-1-derived oligonucleotides by intercellular PRRs, and in particular endosomal TLRs, results in the production of proinflammatory cytokines and antiviral type I IFN, and these proinflammatory responses are differentially regulated in women and men [62 & ].
SEX DIFFERENCES IN TOLL-LIKE RECEPTOR 7-MEDIATED IFNa RESPONSE ARE MODULATED BY ESTROGENS
Initial in-vitro studies have shown significant sex-dependent differences in TLR7-induced IFNa production by pDCs, with higher levels of IFNa production by pDCs from women compared with men [63] . Based on this data, Meier et al. reported sex differences in the IFNa production by pDCs stimulated with HIV-1 and HIV-1-derived TLR7 ligands [9] . This observation of sex-specific differences was restricted to pDCs, and neither myeloid dendritic cells nor monocytes presented sex differences in HIV-1-induced cytokine production. Interestingly, the percentage of IFNa-producing pDCs significantly correlated with plasma progesterone concentrations [9] , indicating a possible role of sex hormones in modulating the TLR7/IFNa pathway in pDCs. In line with this, an important role of estrogen in regulating TLR responsiveness of pDCs has been recently elucidated [13] . In a study by Seillet et al., the transplantation of human female CD34 þ progenitor cells into either female or male humanized NOD/SCID/b2m À/À mice showed that pDCs developing in female mice exhibited an increased frequency of IFNa-producing cells compared with pDCs developing in male mice, indicating that the response of human pDCs is shaped by female sex hormones [13] . To evaluate whether estrogens were responsible for the sex differences in IFNa production in humans, the effect of estrogen treatment in postmenopausal women on TLR7mediated IFNa production by pDCs was analyzed in a longitudinal clinical trial study. 17b-Estradiol treatment markedly enhanced TLR7-dependent production of IFNa by pDCs from postmenopausal women [13] . In a follow-up study, Laffont et al.
showed that blockage of estrogen receptor signaling during pDC development in vitro inhibited TLR7mediated IFNa production by pDCs [64 && ]. Interestingly, X-chromosome dosage contributed to the observed sex bias, as transplanted human pDCs derived from females had an increased TLR7-mediated IFNa production compared with pDCs from males, independent of the sex of the recipient mice [64 && ]. Taken together, these data clearly established an important role for estrogens in regulating innate immune functions and in particular the IFNa response of pDCs to viral infections.
The persistent production of type I IFN by pDCs has been linked to chronic immune activation in HIV-1 infection [65, 66] and correlated with markers of disease progression [43] . The important role of type I IFN in viral pathogenesis was demonstrated in a recent study assessing the role of type I IFN in acute versus chronic lymphocytic choriomeningitis virus (LCMV) infection [67] . Although blocking of IFNa during acute infection had detrimental consequences on the outcome of the LCMV infection, blocking of IFNa during chronic LCMV infection allowed for enhanced immune control [68, 69] . In a humanized mice model, depletion of pDCs in acute HIV-1 infection using a monoclonal antibody abol- ]. These studies reflect the importance of the antiviral effects that IFNa exerts during acute infection, however also show that during persistent infection, the continuous production of IFNa results in an increase in immunopathology. Very recently, the timing of type I IFN-induced immune signatures was analyzed in detail during acute simian immunodeficiency virus-1 infection of rhesus macaques [71 && ]. Blockade of the IFNa/b receptor in acute infection reduced the levels of antiviral gene expression, increased the SIV reservoir size, and accelerated the progression to AIDS, similar to the detrimental effects observed during acute LCMV infection. In contrast, administration of IFNa during primary infection initially prevented systemic infection, though persistent administration resulted in an increase in SIV reservoir size and accelerated disease markers. Altogether, these studies show the importance of IFNa-induced innate responses for the overall disease course of persistent viral infections [71 && ]. Studies assessing the consequences of sex differences in IFNa production in treatment-naïve, HIV-1-infected individuals showed that higher IFNa production in women was associated with higher levels of T cell activation, defined by CD38 þ HLA-DR þ T cells, in women in comparison with men after adjusting for viral load [9] . Given that the expression of T cell activation markers has been shown to predict the rate of untreated HIV-1 disease progression [72, 73] , these data indicate a critical role of the TLR7/IFNa pathway in the sex-specific manifestations of HIV-1 disease. Chang et al. furthermore demonstrated that the higher IFNa production observed in women was also associated with higher expression levels of several ISGs in treatment-naïve, chronically HIV-1-infected individuals [74] . Overall, these data demonstrate that stronger HIV-1-dependent ISG induction in women compared with men, for the same viral load levels [74] , is associated with the higher levels of immune activation observed in HIV-1 infected women, providing a possible mechanism for the faster disease progression described in infected women.
CONCLUSION
Recent studies have started to provide first insights into the pathways by which sex chromosomal factors and sex hormones regulate antiviral immunity, and in particular the type I IFN response to infections, leading to advances in our knowledge of how sex can influence HIV-1-mediated immunopathology. However, there remain large gaps in our understanding of the precise mechanisms leading to sexbased differences in immunity, and how these can be therapeutically modulated. A better understanding of these mechanisms will be critical to take sexspecific factors into consideration when designing experimental and clinical studies in HIV-1-infected populations.
